selçuk cemil öztürk

Specialist Doctor Selcuk Cemil Ozturk

Medical Oncology

Hospital : Medicana Camlica Hospital, Istanbul

Medical Unit : Medical Oncology

Title : Specialist Doctor

Name Surname : Selçuk Cemil Öztürk, Medical Oncology

Graduated from Faculty of Medicine and Year : Ankara University Faculty of Medicine, 1992

Place and Year of Specialization Training
  • skip-track2MoH Ankara Training and Research Hospital Internal Diseases, 1998
  • skip-track2Ankara Numune Training and Research Hospital, Medical Oncology Minor Specialization, 2010
  • skip-track2Άγκυρα Gazi University Medical Oncology Minor Specialization, 2012
Professional experience
  • skip-track2Private Sevgi Hospital, Internal Medicine Specialist, 1998-1999
  • skip-track2Private Bayındır Hospital, Internal Medicine Specialist, 1998-1999
  • skip-track2Adıyaman Training and Research Hospital, Medical Oncology Specialist, 2012-2014
  • skip-track2Medline Antalya Hospital, Medical Oncology Specialist, 2014-2015
  • skip-track2Medicana Samsun Hospital, Medical Oncology Specialist, 2015-2017
  • skip-track2Memorial Ankara Hospital, Medical Oncology Specialist, 2017-2021
  • skip-track2Medicana Camlica Medical Center (Present)
Medical Interests
bottom
    • check-mark-1Breast Cancer,
    • check-mark-1Lung cancer,
    • check-mark-1Colon cancer,
    • check-mark-1Stomach Cancers,
    • check-mark-1Gynecological Cancers,
    • check-mark-1Prostate cancer
Scientific Publications
bottom
    • check-mark-1Clinicopathological features in bilateral breast cancer.
      Baykara M, Ozturk SC, Buyukberber S, Helvaci K, Ozdemir N, Alkis N, Berk V, Koca D, Coskun U, Oksuzoglu B, Uncu D, Arpaci E, Ustaalioglu BO, Demirci U, Kucukoner M, Dogu GG, Alici S, Akman T, Ozkan M, Aslan UY, Durnali AG, Benekli M.Asian Pac J Cancer Prev. 2012;13(9):4571-5. doi: 10.7314/apjcp.2012.13.9.4571.PMID: 23167382
    • check-mark-1Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers.
      Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, Akinci MB, Unal OU, Dane F, Turkoz FP, Balakan O, Eser EP, Ozturk SC, Ozkan M, Oksuzoglu B, Sevinc A, Demir N, Harputluoglu H, Yalcin B, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO).J Gastrointest Surg. 2015 Sep;19(9):1565-71. doi: 10.1007/s11605-015-2888-y. Epub 2015 Jul 16.PMID: 26179664
    • check-mark-1Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma.
      Turan N, Benekli M, Unal OU, Unek İT, Tastekin D, Dane F, Algın E, Ulger S, Eren T, Topcu TO, Turkmen E, Babacan NA, Tufan G, Urakci Z, Ustaalioglu BO, Uysal OS, Ercelep OB, Taskoylu BY, Aksoy A, Canhoroz M, Demirci U, Dogan E, Berk V, Balakan O, Ekinci AŞ, Uysal M, Petekkaya İ, Ozturk SC, Tonyalı Ö, Çetin B, Aldemir MN, Helvacı K, Ozdemir N, Oztop İ, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO).Chin J Cancer Res. 2015 Aug;27(4):408-16. doi: 10.3978/j.issn.1000-9604.2015.08.03.PMID: 26361410
    • check-mark-1Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer.
      Turan N, Benekli M, Dane F, Unal OU, Kara HV, Koca D, Balvan O, Eren T, Tastekin D, Helvaci K, Berk V, Demirci U, Ozturk SC, Dogan E, Cetin B, Kucukoner M, Tonyali O, Tufan G, Oztop I, Gumus M, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO).Thorac Cancer. 2014 Sep;5(5):398-404. doi: 10.1111/1759-7714.12107. Epub 2014 Aug 25.PMID: 26763794
    • check-mark-1 Pathologic and clinical characteristics of elderly patients with breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology).
      Inal A, Akman T, Yaman S, Ozturk SC, Geredeli C, Bilici M, Inanc M, Harputoglu H, Demirci U, Balakan O, Cınkır HY, Alıcı S, Colak D, Sonmez OU, Goksel G, Dogu GG, Engin H, Unal OU, Tamozlu T, Buyukberber S, Boruban CM, Isıkdogan A.Int Surg. 2014 Jan-Feb;99(1):2-7. doi: 10.9738/INTSURG-D-13-00010.PMID: 24444261
    • check-mark-1Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
      Turan N, Benekli M, Ozturk SC, Inal S, Memis L, Guz G, Cetin B, Buyukberber S.Ann Pharmacother. 2012 Oct;46(10):e27. doi: 10.1345/aph.1R160. Epub 2012 Oct 2.PMID: 23032654
    • check-mark-1Is lymph node ratio prognostic factor for survival in elderly patients with node positive breast cancer? The Anatolian Society of Medical Oncology.
      Inal A, Akman T, Yaman S, Ozturk SC, Geredeli C, Bilici M, Inanc M, Harputoglu H, Demirci U, Suner A, Cınkır HY, Alıcı S, Colak D, Sonmez OU, Goksel G, Dogu GG, Engin H, Unal OU, Tamozlu T, Buyukberber S, Boruban CM, Isıkdogan A.Ann Ital Chir. 2013 Mar-Apr;84(2):143-8.PMID: 23698146
    • check-mark-1Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
      Cetin B, Kaplan MA, Berk V, Ozturk SC, Benekli M, Isıkdogan A, Ozkan M, Coskun U, Buyukberber S.Asian Pac J Cancer Prev. 2012;13(3):1059-63. doi: 10.7314/apjcp.2012.13.3.1059.PMID: 22631638
1. Training/certificate information on Good Clinical Practices (ICU) and clinical research:
bottom
    • check-mark-1MSD-ICH GCP Obligaons of Invesgators Conducng Clinical Trials (GCP02 Ver 4.1),04 Nisan 2020
2. Information on the clinical research undertaken:
bottom
    • check-mark-1STOP AND GO STUDY (Colon Cancer-Phase III), Associate Investigator, 2009
    • check-mark-1CAPITELLO (Breast Cancer-Phase III), Associate Investigator, 2019- 2021
    • check-mark-1RIGHT CHOICE (Breast Cancer-Phase III), Associate Investigator, 2020-2021
    • check-mark-1IPATUNITY 170 (Breast Cancer-Phase III), Associate Investigator, 2020-2021
    • check-mark-1MK3475-975 (Esophagus-Phase III), Assistant Investigator, 2020-2021
    • check-mark-1MK7339-012 (Lung Cancer – Phase III), Associate Investigator, 2021-2021
    • check-mark-1MK7902-017 (Colorectal Cancer – Phase III), Associate Investigator, 2021 -2021
    • check-mark-1CA209-7FL (Breast Cancer – Phase III), Associate Investigator, 2021-2021
    • check-mark-1MK7902-017 (Colorectal Cancer – Phase III), Associate Investigator, 2021 -2021
    • check-mark-1WO42312 (Breast Cancer – Phase II), Associate Investigator, 2021- 2021
    • check-mark-1MO42319 (Breast Cancer – Phase III), Associate Investigator, 2021- 2021
    • check-mark-1GO42661 (Biliary Tract Cancer – Phase II), Associate Investigator, 2021- 2021
    • check-mark-1INCMGA0012-304 (Lung Cancer – Phase III), Associate Investigator, 2021- 2021